Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 7Recruiting 6Active not recruiting 5Terminated 4Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Dermatologic 6Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 51Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 27Carcinoma, Hepatocellular 18Neoplasms 15Neoplasm Metastasis 15Lung Neoplasms 14Colorectal Neoplasms 14Stomach Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Kidney Neoplasms 6Esophageal Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

pembrolizumab 8Nivolumab 6Ipilimumab 6cemiplimab 4aldesleukin 3Interleukin-2 3Blood Specimen Collection 3fludarabine 2Specimen Handling 2HhAntag691 2Cyclophosphamide 2Biopsy 2trametinib 1spartalizumab 1sonidegib 1pertuzumab 1lifileucel 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1dabrafenib 1brodalumab 1atezolizumab 1Vitamin A 1Trastuzumab 1Tissue Banks 1Surgical Procedures, Operative 1Standard of Care 1Second Harmonic Generation Microscopy 1Resistance Training 1Red Light 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Skin Neoplasms × Nivolumab × Clear all
NCT05779423 2026-05-19

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Massachusetts General Hospital

Phase 2 Recruiting
37 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
29 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT07422779 2026-02-20

MAK

Institute of Oncology Ljubljana

Phase NA Recruiting
100 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Intergruppo Melanoma Italiano

Recruiting
270 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

University Health Network, Toronto

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡